{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T20:38:11Z","timestamp":1769719091708,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T00:00:00Z","timestamp":1766880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research on the Expression and Significance of USP9X in Multiple Myeloma","award":["20240303040410"],"award-info":[{"award-number":["20240303040410"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hereditas"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ubiquitination-related genes (UbRGs) play critical roles in tumor biology. However, their functions in multiple myeloma (MM) remain insufficiently explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Transcriptomic data from public databases were integrated to identify UbRGs in MM through WGCNA, differential expression, and protein\u2013protein interaction (PPI) analyses. Functional roles were examined by GO, KEGG, and GSEA, while immune infiltration and drug sensitivity were evaluated using CIBERSORT, ESTIMATE, and OncoPredict. UbRG expression was validated in clinical samples and cell lines by qRT-PCR and western blot, and functional effects of UbRG knockdown in MM cells were examined using CCK-8, Transwell, EdU, and TUNEL assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ring Finger Protein 25 (RNF25) is a ubiquitination-related gene closely associated with MM, exhibiting consistent overexpression across multiple independent datasets. Elevated RNF25 expression is significantly correlated with poorer overall survival and serves as an independent adverse prognostic factor. Functional enrichment analysis revealed that RNF25 may regulate key pathways such as ATP-dependent chromatin remodeling, cell cycle progression, and ubiquitin-mediated proteolysis. Immune analysis further indicated that high RNF25 expression is associated with reduced immune and stromal scores, increased plasma cell infiltration, and elevated T cell co-inhibition activity. RNF25 was highly expressed in tumor tissues from clinical samples, and its knockdown significantly reduced the viability, proliferation, and migration of U266 cells, while promoting apoptosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RNF25 may serve as a potential prognostic biomarker for MM and holds promise as a candidate therapeutic target.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41065-025-00631-0","type":"journal-article","created":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T01:34:24Z","timestamp":1766885664000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["RNF25 serves as a novel diagnostic and prognostic biomarker in multiple myeloma: a multi-cohort integrative analysis"],"prefix":"10.1186","volume":"163","author":[{"given":"Bowen","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuyue","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lunbi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanzhang","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,28]]},"reference":[{"issue":"Suppl 2","key":"631_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70067","volume":"43","author":"F Gay","year":"2025","unstructured":"Gay F, Marchetti E, Bertuglia G. Multiple myeloma unpacked. Hematol Oncol. 2025;43(Suppl 2):e70067. https:\/\/doi.org\/10.1002\/hon.70067.","journal-title":"Hematol Oncol"},{"key":"631_CR2","doi-asserted-by":"publisher","unstructured":"He L, Yu C, Qin S, Zheng E, Liu X, Liu Y et al. The proteasome component PSMD14 drives myelomagenesis through a histone deubiquitinase activity. Mol Cell. 2023;83(22):4000-16 e6. https:\/\/doi.org\/10.1016\/j.molcel.2023.10.019","DOI":"10.1016\/j.molcel.2023.10.019"},{"issue":"6","key":"631_CR3","first-page":"373","volume":"95","author":"TC Michels","year":"2017","unstructured":"Michels TC, Petersen KE. Multiple myeloma: diagnosis and treatment. Am Fam Physician. 2017;95(6):373\u201383.","journal-title":"Am Fam Physician"},{"issue":"1","key":"631_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","volume":"5","author":"Q Lu","year":"2024","unstructured":"Lu Q, Yang D, Li H, Niu T, Tong A. Multiple myeloma: signaling pathways and targeted therapy. Mol Biomed. 2024;5(1):25. https:\/\/doi.org\/10.1186\/s43556-024-00188-w.","journal-title":"Mol Biomed"},{"issue":"4","key":"631_CR5","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1172\/JCI129205","volume":"130","author":"SA Minnie","year":"2020","unstructured":"Minnie SA, Hill GR. Immunotherapy of multiple myeloma. J Clin Invest. 2020;130(4):1565\u201375. https:\/\/doi.org\/10.1172\/JCI129205.","journal-title":"J Clin Invest"},{"issue":"5","key":"631_CR6","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","volume":"2","author":"G Lancman","year":"2021","unstructured":"Lancman G, Sastow DL, Cho HJ, Jagannath S, Madduri D, Parekh SS, et al. Bispecific antibodies in multiple myeloma: present and future. Blood Cancer Discov. 2021;2(5):423\u201333. https:\/\/doi.org\/10.1158\/2643-3230.BCD-21-0028.","journal-title":"Blood Cancer Discov"},{"issue":"8","key":"631_CR7","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086\u2013107. https:\/\/doi.org\/10.1002\/ajh.26590.","journal-title":"Am J Hematol"},{"issue":"3","key":"631_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/oncolo\/oyad306","volume":"29","author":"A Rafae","year":"2024","unstructured":"Rafae A, van Rhee F, Al Hadidi S. Perspectives on the treatment of multiple myeloma. Oncologist. 2024;29(3):200\u201312. https:\/\/doi.org\/10.1093\/oncolo\/oyad306.","journal-title":"Oncologist"},{"key":"631_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13123079","author":"G LaPlante","year":"2021","unstructured":"LaPlante G, Zhang W. Targeting the ubiquitin-proteasome system for cancer therapeutics by small-molecule inhibitors. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13123079.","journal-title":"Cancers"},{"issue":"6","key":"631_CR10","doi-asserted-by":"publisher","first-page":"6521","DOI":"10.18632\/oncotarget.6658","volume":"7","author":"S Lub","year":"2016","unstructured":"Lub S, Maes K, Menu E, De Bruyne E, Vanderkerken K, Van Valckenborgh E. Novel strategies to target the ubiquitin proteasome system in multiple myeloma. Oncotarget. 2016;7(6):6521\u201337. https:\/\/doi.org\/10.18632\/oncotarget.6658.","journal-title":"Oncotarget"},{"key":"631_CR11","doi-asserted-by":"publisher","unstructured":"Roy P, Sarkar UA, Basak S. The NF-kappaB activating pathways in multiple myeloma. Biomedicines. 2018;6(2). https:\/\/doi.org\/10.3390\/biomedicines6020059.","DOI":"10.3390\/biomedicines6020059"},{"issue":"13","key":"631_CR12","doi-asserted-by":"publisher","first-page":"5528","DOI":"10.1158\/0008-5472.CAN-09-4229","volume":"70","author":"Z Jagani","year":"2010","unstructured":"Jagani Z, Wiederschain D, Loo A, He D, Mosher R, Fordjour P, et al. The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells. Cancer Res. 2010;70(13):5528\u201338. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-4229.","journal-title":"Cancer Res"},{"issue":"11","key":"631_CR13","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.tibs.2025.07.009","volume":"50","author":"P Ebadi","year":"2025","unstructured":"Ebadi P, Stratton CM, Olsen SK. E3 ubiquitin ligases in signaling, disease, and therapeutics. Trends Biochem Sci. 2025;50(11):960\u201376. https:\/\/doi.org\/10.1016\/j.tibs.2025.07.009.","journal-title":"Trends Biochem Sci"},{"key":"631_CR14","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559. https:\/\/doi.org\/10.1186\/1471-2105-9-559.","journal-title":"BMC Bioinformatics"},{"issue":"7","key":"631_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. https:\/\/doi.org\/10.1093\/nar\/gkv007.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"631_CR16","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. ClusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137. https:\/\/doi.org\/10.1089\/omi.2011.0118.","journal-title":"OMICS"},{"issue":"5","key":"631_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137. https:\/\/doi.org\/10.1038\/nmeth.3337.","journal-title":"Nat Methods"},{"issue":"1","key":"631_CR18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s13046-018-1002-1","volume":"37","author":"Y He","year":"2018","unstructured":"He Y, Jiang Z, Chen C, Wang X. Classification of triple-negative breast cancers based on immunogenomic profiling. J Exp Clin Cancer Res. 2018;37(1):327. https:\/\/doi.org\/10.1186\/s13046-018-1002-1.","journal-title":"J Exp Clin Cancer Res"},{"key":"631_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab260","author":"D Maeser","year":"2021","unstructured":"Maeser D, Gruener RF, Huang RS. Oncopredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021. https:\/\/doi.org\/10.1093\/bib\/bbab260.","journal-title":"Brief Bioinform"},{"issue":"8","key":"631_CR20","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.3324\/haematol.2023.283058","volume":"109","author":"M Engelhardt","year":"2024","unstructured":"Engelhardt M, Kortum KM, Goldschmidt H, Merz M. Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible. Haematologica. 2024;109(8):2420\u201335. https:\/\/doi.org\/10.3324\/haematol.2023.283058.","journal-title":"Haematologica"},{"issue":"13","key":"631_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202406962","volume":"12","author":"C Zhang","year":"2025","unstructured":"Zhang C, Tian C, Zhu R, Chen C, Jin C, Wang X, et al. CircSATB1 promotes colorectal cancer liver metastasis through facilitating FKBP8 degradation via RNF25-mediated ubiquitination. Adv Sci. 2025;12(13):e2406962. https:\/\/doi.org\/10.1002\/advs.202406962.","journal-title":"Adv Sci"},{"issue":"13","key":"631_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202306929","volume":"11","author":"Z Huang","year":"2024","unstructured":"Huang Z, Zhou L, Duan J, Qin S, Jiang J, Chen H, et al. Oxidative stress promotes liver cancer metastasis via RNF25-mediated E-cadherin protein degradation. Adv Sci. 2024;11(13):e2306929. https:\/\/doi.org\/10.1002\/advs.202306929.","journal-title":"Adv Sci"},{"issue":"6","key":"631_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0651-5","volume":"9","author":"JH Cho","year":"2018","unstructured":"Cho JH, You YM, Yeom YI, Lee DC, Kim BK, Won M, et al. RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-\u03baB-mediated ERK reactivation. Cell Death Dis. 2018;9(6):587. https:\/\/doi.org\/10.1038\/s41419-018-0651-5.","journal-title":"Cell Death Dis"},{"issue":"7","key":"631_CR24","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.3390\/curroncol31070296","volume":"31","author":"M Jezierzanski","year":"2024","unstructured":"Jezierzanski M, Nafalska N, Stopyra M, Furgol T, Miciak M, Kabut J, et al. Temozolomide (TMZ) in the treatment of glioblastoma Multiforme-A literature review and clinical outcomes. Curr Oncol (Toronto Ont). 2024;31(7):3994\u20134002. https:\/\/doi.org\/10.3390\/curroncol31070296.","journal-title":"Curr Oncol (Toronto Ont)"},{"issue":"36","key":"631_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202303484","volume":"10","author":"S Feng","year":"2023","unstructured":"Feng S, Rao Z, Zhang J, She X, Chen Y, Wan K, et al. Inhibition of CARM1-mediated methylation of ACSL4 promotes ferroptosis in colorectal cancer. Adv Sci. 2023;10(36):e2303484. https:\/\/doi.org\/10.1002\/advs.202303484.","journal-title":"Adv Sci"},{"issue":"20","key":"631_CR26","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2217\/epi-2023-0234","volume":"15","author":"X Chai","year":"2023","unstructured":"Chai X, Tao Q, Li L. The role of RING finger proteins in chromatin remodeling and biological functions. Epigenomics. 2023;15(20):1053\u201368. https:\/\/doi.org\/10.2217\/epi-2023-0234.","journal-title":"Epigenomics"},{"key":"631_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232112815","author":"FL Zhang","year":"2022","unstructured":"Zhang FL, Li DQ. Targeting chromatin-remodeling factors in cancer cells: promising molecules in cancer therapy. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232112815.","journal-title":"Int J Mol Sci"},{"key":"631_CR28","doi-asserted-by":"publisher","unstructured":"Morawska M, Kielbus M, Paziewska M, Szelest M, Karczmarczyk A, Zaleska J, et al. Mutations of ARID1B, PIK3C2B, KMT2B, and FAT1 genes influence clinical outcome in newly diagnosed myeloma. Cancer Genet. 2024;288\u20139. https:\/\/doi.org\/10.1016\/j.cancergen.2024.11.001.","DOI":"10.1016\/j.cancergen.2024.11.001"},{"key":"631_CR29","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00488-18","author":"CC So","year":"2019","unstructured":"So CC, Ramachandran S, Martin A. E3 ubiquitin ligases RNF20 and RNF40 are required for double-stranded break (DSB) repair: evidence for monoubiquitination of histone H2B lysine 120 as a novel axis of DSB signaling and repair. Mol Cell Biol. 2019. https:\/\/doi.org\/10.1128\/MCB.00488-18.","journal-title":"Mol Cell Biol"},{"issue":"4","key":"631_CR30","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.cell.2006.04.029","volume":"125","author":"R Pavri","year":"2006","unstructured":"Pavri R, Zhu B, Li G, Trojer P, Mandal S, Shilatifard A, et al. Histone H2B monoubiquitination functions cooperatively with FACT to regulate elongation by RNA polymerase II. Cell. 2006;125(4):703\u201317. https:\/\/doi.org\/10.1016\/j.cell.2006.04.029.","journal-title":"Cell"},{"issue":"2","key":"631_CR31","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41418-020-00648-0","volume":"28","author":"F Dang","year":"2021","unstructured":"Dang F, Nie L, Wei W. Ubiquitin signaling in cell cycle control and tumorigenesis. Cell Death Differ. 2021;28(2):427\u201338. https:\/\/doi.org\/10.1038\/s41418-020-00648-0.","journal-title":"Cell Death Differ"},{"issue":"5","key":"631_CR32","doi-asserted-by":"publisher","first-page":"909","DOI":"10.7150\/ijbs.31972","volume":"15","author":"T Zhou","year":"2019","unstructured":"Zhou T, Yi F, Wang Z, Guo Q, Liu J, Bai N, et al. The functions of DNA damage factor RNF8 in the pathogenesis and progression of cancer. Int J Biol Sci. 2019;15(5):909\u201318. https:\/\/doi.org\/10.7150\/ijbs.31972.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"631_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00312-6","volume":"5","author":"H Yu","year":"2020","unstructured":"Yu H, Lin L, Zhang Z, Zhang H, Hu H. Targeting NF-kappaB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct Target Ther. 2020;5(1):209. https:\/\/doi.org\/10.1038\/s41392-020-00312-6.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"631_CR34","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.7150\/ijbs.115032","volume":"21","author":"L Li","year":"2025","unstructured":"Li L, Wang Z, Ma B, Ye Q, Lei Y, Lu M, et al. <article-title update=\"added\">BAY11-7082 targets RNF25 to reverse TRIP4 ubiquitination-dependent NF-\u03baB activation and apoptosis resistance in renal cell carcinoma. Int J Biol Sci. 2025;21(10):4410\u201327. https:\/\/doi.org\/10.7150\/ijbs.115032.","journal-title":"Int J Biol Sci"},{"issue":"15","key":"631_CR35","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.1111\/febs.16068","volume":"289","author":"T Perini","year":"2022","unstructured":"Perini T, Materozzi M, Milan E. The immunity-malignancy equilibrium in multiple myeloma: lessons from oncogenic events in plasma cells. FEBS J. 2022;289(15):4383\u201397. https:\/\/doi.org\/10.1111\/febs.16068.","journal-title":"FEBS J"},{"key":"631_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216491","author":"A Melaccio","year":"2022","unstructured":"Melaccio A, Reale A, Saltarella I, Desantis V, Lamanuzzi A, Cicco S, et al. Pathways of angiogenic and inflammatory cytokines in multiple myeloma: role in plasma cell clonal expansion and drug resistance. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11216491.","journal-title":"J Clin Med"},{"issue":"7","key":"631_CR37","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","volume":"19","author":"WH Fridman","year":"2022","unstructured":"Fridman WH, Meylan M, Petitprez F, Sun CM, Italiano A, Sautes-Fridman C. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol. 2022;19(7):441\u201357. https:\/\/doi.org\/10.1038\/s41571-022-00619-z.","journal-title":"Nat Rev Clin Oncol"},{"key":"631_CR38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.coi.2014.02.009","volume":"28","author":"VD Dang","year":"2014","unstructured":"Dang VD, Hilgenberg E, Ries S, Shen P, Fillatreau S. From the regulatory functions of B cells to the identification of cytokine-producing plasma cell subsets. Curr Opin Immunol. 2014;28:77\u201383. https:\/\/doi.org\/10.1016\/j.coi.2014.02.009.","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"631_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05635-4","volume":"22","author":"J Sun","year":"2024","unstructured":"Sun J, Shi S, Sun C, Wang J, Yang X, Yang Z, et al. Predictive nomogram of the clinical outcomes of colorectal cancer based on methylated SEPT9 and intratumoral IL-10(+) Tregs infiltration. J Transl Med. 2024;22(1):861. https:\/\/doi.org\/10.1186\/s12967-024-05635-4.","journal-title":"J Transl Med"},{"issue":"5","key":"631_CR40","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.it.2012.12.002","volume":"34","author":"H Frebel","year":"2013","unstructured":"Frebel H, Oxenius A. The risks of targeting co-inhibitory pathways to modulate pathogen-directed T cell responses. Trends Immunol. 2013;34(5):193\u20139. https:\/\/doi.org\/10.1016\/j.it.2012.12.002.","journal-title":"Trends Immunol"},{"issue":"4","key":"631_CR41","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1182\/blood-2012-02-412510","volume":"120","author":"WJ Norde","year":"2012","unstructured":"Norde WJ, Hobo W, van der Voort R, Dolstra H. Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. Blood. 2012;120(4):728\u201336. https:\/\/doi.org\/10.1182\/blood-2012-02-412510.","journal-title":"Blood"},{"issue":"6","key":"631_CR42","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1172\/JCI46102","volume":"121","author":"L Baitsch","year":"2011","unstructured":"Baitsch L, Baumgaertner P, Devevre E, Raghav SK, Legat A, Barba L, et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J Clin Invest. 2011;121(6):2350\u201360. https:\/\/doi.org\/10.1172\/JCI46102.","journal-title":"J Clin Invest"},{"issue":"1","key":"631_CR43","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s40478-025-02046-4","volume":"13","author":"H Li","year":"2025","unstructured":"Li H, Wu Y, Chen Y, Lv J, Qu C, Mei T, et al. Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights. Acta Neuropathol Commun. 2025;13(1):126. https:\/\/doi.org\/10.1186\/s40478-025-02046-4.","journal-title":"Acta Neuropathol Commun"},{"issue":"20","key":"631_CR44","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1182\/blood.2019003073","volume":"135","author":"M Baron","year":"2020","unstructured":"Baron M, Belin L, Cassoux N, Fardeau C, Blaizeau M, Soussain C, et al. Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma. Blood. 2020;135(20):1811\u20135. https:\/\/doi.org\/10.1182\/blood.2019003073.","journal-title":"Blood"},{"issue":"14","key":"631_CR45","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1200\/JCO.2015.64.8634","volume":"34","author":"J Glass","year":"2016","unstructured":"Glass J, Won M, Schultz CJ, Brat D, Bartlett NL, Suh JH, et al. Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227. J Clin Oncol. 2016;34(14):1620\u20135. https:\/\/doi.org\/10.1200\/JCO.2015.64.8634.","journal-title":"J Clin Oncol"},{"issue":"4","key":"631_CR46","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/hon.2648","volume":"37","author":"ZY Liu","year":"2019","unstructured":"Liu ZY, Tian MY, Deng L, Wang YS, Xing R, Liu H, et al. The potential diagnostic power of CD138\u2009+\u2009microparticles from the plasma analysis for multiple myeloma clinical monitoring. Hematol Oncol. 2019;37(4):401\u20138. https:\/\/doi.org\/10.1002\/hon.2648.","journal-title":"Hematol Oncol"}],"container-title":["Hereditas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-025-00631-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00631-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00631-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T09:33:11Z","timestamp":1769679191000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41065-025-00631-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,28]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["631"],"URL":"https:\/\/doi.org\/10.1186\/s41065-025-00631-0","relation":{},"ISSN":["1601-5223"],"issn-type":[{"value":"1601-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,28]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of The Second Affiliated Hospital of Qiqihar Medical University (approval number: (Qi) ethics approval [2024] No. 86) in accordance with Declaration of Helsinki, and written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}